TriSalus Life Sciences (NASDAQ:TLSIW) Trading Down 10.1% – Here’s What Happened

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW)’s stock price dropped 10.1% on Wednesday . The stock traded as low as $0.4551 and last traded at $0.6630. Approximately 3,015 shares were traded during mid-day trading, a decline of 35% from the average daily volume of 4,616 shares. The stock had previously closed at $0.7375.

TriSalus Life Sciences Stock Down 6.0%

The company’s fifty day moving average is $0.94 and its two-hundred day moving average is $1.20.

Institutional Trading of TriSalus Life Sciences

Several hedge funds have recently added to or reduced their stakes in TLSIW. Cerity Partners LLC acquired a new stake in TriSalus Life Sciences in the fourth quarter valued at approximately $1,374,000. Citadel Advisors LLC increased its stake in TriSalus Life Sciences by 439.0% in the third quarter. Citadel Advisors LLC now owns 126,876 shares of the company’s stock valued at $199,000 after purchasing an additional 103,336 shares during the last quarter. Aristeia Capital L.L.C. purchased a new position in TriSalus Life Sciences in the fourth quarter valued at approximately $43,000. Finally, Fort Baker Capital Management LP purchased a new position in TriSalus Life Sciences in the fourth quarter valued at approximately $44,000.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage medical device company focused on developing minimally invasive technologies to enhance the precision and efficacy of cancer radiation therapy. The company’s lead product, the TriMark™ Tissue Marker System, is designed to provide high-visibility soft-tissue fiducial markers that assist oncologists in accurately targeting tumors during radiotherapy. By deploying bio-absorbable markers directly into tumor beds, TriSalus aims to improve treatment planning, patient comfort and long-term follow-up imaging.

Founded in 2015 and headquartered in Plymouth, Minnesota, TriSalus Life Sciences pursues a platform approach to oncology treatment, with research and development efforts centered on novel delivery devices and advanced imaging solutions.